SCHEMBL6416985

SCHEMBL6416985

C(=NNc1nc2nonc2nc1NCc1ccccc1)c1ccco1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.51
KMT2A Q03164 8/20 0.51
SMN1; SMN2 Q16637 7/20 0.51
MEN1 O00255 7/20 0.51
KDM4E B2RXH2 5/20 0.51
LMNA P02545 3/20 0.51
MAPK1 P28482 2/20 0.51
HTT P42858 1/20 0.51
BLM P54132 1/20 0.51
PKM P14618 1/20 0.46
GAA P10253 8/20 0.44
TDP1 Q9NUW8 4/20 0.44
MAOB P27338 2/20 0.44
MAOA P21397 1/20 0.44
NPC1 O15118 6/20 0.43
RAB9A P51151 5/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6416975 1.00 MAPT (0.51) MAPTKMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL6421048 0.82 GAA (0.49) MAPTKMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL3055383 0.82 GAA (0.49) MAPTKMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL6414195 0.81 MAPT (0.40) MAPTKMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL6414183 0.81 MAPT (0.40) MAPTKMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL6510185 0.81 BIRC5 (0.50) MAPTKMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL6414665 0.80 DDX3X (0.53) MAPTKMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL6414142 0.80 MAPT (0.43) MAPTKMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL6433093 0.79 GAA (0.45) MAPTKMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL26034950 0.78 KMT2A (0.58) MAPTKMT2ASMN1; SMN2MEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885KMT2A 3640/4885SMN1; SMN2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.